Pirfenidone Capsule, 267 Mg Capsule
Product Images NDC 33342-461

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Pirfenidone Capsule, 267 Mg (NDC 33342-461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Pirfenidone 267 mg Outer Carton 63s Capsules)

Outer carton label for Pirfenidone Capsules, USP 267 mg by Macleods Pharmaceuticals Limited. The 14-day titration pack contains 63 capsules, with dosing instructions for two weeks. The carton includes manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India. The label notes storage instructions and caution to keep out of reach of children.*

FDA Label Image

Pirfenidone-fig-01 (Pirfenidone 267mg Fig 01)

A cumulative distribution plot showing the percentage of patients versus the absolute change in percent forced vital capacity (%FVC) from baseline to week 52. The graph compares two groups: Pirfenidone (n=278) represented by a solid line, and placebo (n=277) represented by a dotted line. The chart highlights patient proportions experiencing worsening (decrease in %FVC) or no decline (increase in %FVC) over the study period.*

FDA Label Image

1 (Pirfenidone 267mg Inner Carton 21s 01)

Label of inner carton for Pirfenidone Capsules USP 267 mg by Macleods Pharmaceuticals Limited. The carton states a count of 21 capsules arranged as 7 strips of 3 unit-dose capsules. The label includes the NDC number 33342-461-35 and highlights 'Week 1 Dosing' and the strength 267 mg in green. Manufacturer details and storage instructions are also visible.*

FDA Label Image

1 (Pirfenidone 267mg Inner Carton 42 Capsules)

Label of inner carton for Pirfenidone Capsules USP 267 mg by Macleods Pharmaceuticals Limited. The carton contains 42 capsules (7 x 6 unit-dose) with Week 2 Dosing prominently marked. Manufactured for Macleods Pharma USA, Inc., Princeton, NJ. Storage instructions and usual dosage advisory noted. Includes barcode and NDC 33342-461-36.*

FDA Label Image

1 (Pirfenidone 267mg Inner Carton Mainta Packs)

Label of inner carton for Pirfenidone Capsules, USP 267 mg, containing 63 capsules (7 x 9 unit-dose). The label shows the product name and strength prominently, with Macleods Pharma USA as the manufacturer. It includes storage instructions, usual dosage notice, and a barcode. The pack is marked as a Maintenance Pack.*

FDA Label Image

1 (Pirfenidone 267mg Outer Carton Mainta Pack)

Packaging label for Pirfenidone Capsules USP 267 mg by Macleods Pharmaceuticals Limited. The label indicates a 4-week maintenance pack containing 28 blister cards, totaling 252 capsules (9 capsules per blister). It is labeled for oral use and includes storage and dosage instruction references.*

FDA Label Image

111 (Pirfenidone Capsules 267mg)

Label for Pirfenidone Capsules, USP 267 mg, manufactured by Macleods Pharmaceuticals Limited. The label displays the strength (267 mg) prominently, dosage form as capsules, and packaging size of 270 capsules. It includes storage instructions and manufacturer details for Macleods Pharma USA, Inc.*

FDA Label Image

Pirfenidone-fig-02 (Pirfenidone Fig 02)

A line graph showing the mean change in FVC (mL) over 52 weeks for Pirfenidone compared to placebo. The x-axis represents weeks (0 to 52), and the y-axis represents the mean change in FVC in mL. Pirfenidone (solid line, n=278) shows a slower decline in FVC compared to placebo (dashed line, n=277), which has a steeper decline over time.*

FDA Label Image

Pirfenidone-fig-03 (Pirfenidone Fig 03)

A Kaplan-Meier survival curve chart comparing percentage of patients alive over time (in weeks) between two groups: Pirfenidone (263 patients) and Placebo (624 patients). The chart includes a hazard ratio (HR) with 95% confidence interval (CI) and a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Pirfenidone-str (Pirfenidone Str)

Chemical structure of Pirfenidone, the active ingredient in Pirfenidone Capsule 267 mg. The diagram shows the molecular arrangement with a methyl group, carbonyl group, and nitrogen linkage between two aromatic rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.